# Centauri Therapeutics Limited

Centauri Therapeutics Limited is an other based in Alderley Park, Cheshire, United Kingdom.

## Overview

- **Organization type:** other
- **Headquarters:** Alderley Park, Cheshire, United Kingdom
- **Region:** Europe
- **Address:** Alderley Park, Nether Alderley, Cheshire SK10 4TG, United Kingdom
- **Assets under management:** Undisclosed
- **Website:** centauritherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/centauri-therapeutics-limited

## Regulatory record

- **Reports private funds:** No

## About

Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology. The company uses its proprietary Alphamer technology to treat life-threatening diseases. Centauri has received funding from various sources, including the AMR Action Fund and CARB-X, to support the progression of its lead clinical candidate.

## Sectors

- Biotechnology
- Therapeutics
- Infectious Disease
- Oncology

## People

- Jennifer Schneider — Team Member (PhD, MPH)
- Helen Bright — Team Member (PhD, FRSM)
- Debra Barker — Team Member (MD, MSc)
- Samantha Macro — Team Member (PhD, MCA, MBA)
- Hassan Al-Bewani — Team Member (PhD)
- Antonia Atkinson — Team Member
- Jessica Boyle — Team Member (PhD, MBA)
- Matthew Bushdyhan — Team Member (MRes)
- David Chapman — Team Member (PhD)
- Zenobia D’Costa — Team Member (PhD)
- Iman Hassanally — Strategy and Corporate Development Manager
- Daniel Hynes — Team Member (BSc)
- Adam Johnson — Team Member (PhD)
- Lydia Jones — Team Member (PhD)
- Khushi Khare — Team Member
- Jaya Saini — Team Member (PhD)

## Questions

### Who runs investment decisions at Centauri Therapeutics?

The company's team page lists senior scientists and a strategy manager, but Centauri has not publicly named a CEO, CIO, or managing principal. Investment decisions appear to rest with the listed leadership, including PhD-level researchers and the Strategy and Corporate Development Manager Iman Hassanally (per firm website).

### How does Centauri Therapeutics source its funding?

The firm raises capital through venture rounds and non-dilutive grants. In February 2026, it extended its Series A to £30M with a £6M investment from the AMR Action Fund. It also receives grant funding from CARB-X, including a $5.1M award in July 2025 (per firm press releases).

### Which sectors does Centauri explicitly avoid?

Centauri's public focus is limited to infectious diseases and oncology. The firm has not disclosed any sectors it explicitly avoids, but based on its pipeline and press releases, it does not appear active in areas such as gene therapy, rare diseases, or medical devices.

### What regulatory milestones has Centauri achieved?

Centauri's lead candidate CTX-187 received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, which provides expedited development and regulatory pathways (per firm press release, March 2026).

## Related profiles

- [BioClinica - CCBR-SYNARC Inc.](https://altss.com/profile/bioclinica-ccbr-synarc-inc)
- [Digital Reasoning Systems](https://altss.com/profile/digital-reasoning-systems)

---

Last updated: 2026-07-10T21:24:44.000Z

Canonical page: https://altss.com/profile/centauri-therapeutics-limited

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology